Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27269191 | 0.86 | KDM1A (0.31) | — | |
| SCHEMBL27306256 | 0.85 | SLC6A2 (0.36) | TSHRSMN1; SMN2 | |
| SCHEMBL27267906 | 0.83 | TSHR (0.37) | TSHR | |
| SCHEMBL25001375 | 0.79 | — | — | |
| SCHEMBL27307717 | 0.78 | CYP2D6 (0.31) | CYP2D6SMN1; SMN2 | |
| SCHEMBL27349654 | 0.78 | TSHR (0.46) | TSHRHIF1AMAPK1CYP2D6SMN1; SMN2 | |
| SCHEMBL25822472 | 0.77 | TSHR (0.33) | TSHRCYP2D6SMN1; SMN2 | |
| SCHEMBL24589644 | 0.76 | KDM4E (0.40) | TSHRCYP2D6 | |
| SCHEMBL25001374 | 0.74 | OPRM1 (0.35) | TSHRHIF1AMAPK1CYP2D6SMN1; SMN2 | |
| SCHEMBL1753867 | 0.74 | TSHR (0.43) | TSHRHIF1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | TSHR 1968/4885HIF1A 3211/4885MAPK1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.